Company Filing History:
Years Active: 2020-2022
Title: Innovations by James R Beasley
Introduction
James R Beasley is a notable inventor based in Doylestown, PA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target metabolic disorders. With a total of 2 patents, his work focuses on non-systemic TGR5 agonists that have potential applications in treating diabetic diseases.
Latest Patents
James R Beasley’s latest patents include innovative sulfonamide compounds and tricyclic compounds. The first patent relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. These compounds are identified as useful non-systemic TGR5 agonists that can be employed in the treatment of diabetic diseases in humans. The invention also provides a pharmaceutical composition containing these sulfonamide compounds and outlines methods for their production and use in treating patients with metabolic disorders. Additionally, the second patent focuses on tricyclic compounds of formula (I) and formula (II), which similarly serve as non-systemic TGR5 agonists for treating diabetic diseases. This patent also includes a pharmaceutical composition and methods for utilizing these compounds in conjunction with other anti-diabetic drugs.
Career Highlights
James R Beasley is currently associated with Venenum Biodesign, LLC, where he continues to innovate in the field of drug development. His work is characterized by a commitment to addressing significant health challenges through scientific research and invention.
Collaborations
James has collaborated with notable colleagues such as Chia-Yu Huang and Brian F McGuinness, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
James R Beasley exemplifies the spirit of innovation in the pharmaceutical industry through his groundbreaking work on TGR5 agonists. His contributions are poised to make a meaningful impact on the treatment of metabolic disorders.